Type 1 and type 2 cervical carcinomas: Some cervical cancers are more difficult to prevent with screening

Cytopathology

Volumn 23, Issue 1, 2012, Pages 6-12

  Austin, R M ^a   Zhao, C ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cervical carcinoma; Cervical screening; Litigation; Pap cytology

Indexed keywords

WART VIRUS VACCINE;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER PREVENTION; CANCER SCREENING; FALSE NEGATIVE RESULT; FEMALE; HISTOPATHOLOGY; HUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CARCINOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84855969338     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/j.1365-2303.2011.00955.x     Document Type: Review

References (63)

1. US Preventive Services Task Force. Screening for cervical cancer: recommendations and rationale. In: Guide to Clinical Preventive Services, 3rd edn. Rockville, MD: Agency for Healthcare Research and Quality; 2003.
2. Gustaffson L, Ponten J, Zack M, Adami HO. International incidence rates of cervical cancer after introduction of cytological screening. Cancer Causes Control 1997;8:755-63.
3. McCrory DC, Mather DB, Bastian L et al. Evaluation of Cervical Cytology. Evidence report/technology assessment No. 5 (prepared by Duke University under contract No. 290-97-0014.) AHCPR Publication No. 99-E010. Rockville, MD: Agency for Health Care Policy and Research; 1999.
4. Schiffman M, Wentzensen N. From human papillomavirus to cervical cancer. Obstet Gynecol 2010;116:177-85.
5. McCredie MR, Sharpless KJ, Paul C et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9:425-34.
6. Tidbury P, Singer A, Jenkins D. CIN3: the role of lesion size in invasion. Br J Obstet Gynaecol 1992;99:583-6.
7. IARC Working Group on evaluation of cervical cancer screening programmes. Screening for squamous cervical cancer: duration of risk after negative results of cervical cytology and its implication for screening policies. IARC Working Group on evaluation of cervical cancer screening programmes. Br Med J (Clin Res Ed) 1986;293:659-64.
8. Kulasingam SL, Havrilesky L, Ghebre R, Myers ER. Screening for Cervical Cancer: A Decision Analysis for the US Preventive Services Task Force. AHRQ Publication No. 11-05157-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
9. Austin RM, Zhao C. Observations from Pap litigation consultations. Pathol Case Rev 2011;16:73-82.
10. Austin RM, Holladay EB. Chapter X. Lessons from litigation. In: The Pap Test. DeMay RM (ed.). Chicago, IL: ASCP Press; 2005: 249-60.
11. Laskey PW, Meigs JW, Flannery JT. Uterine cervical carcinoma in Connecticut, 1935-1973: evidence for two classes of invasive disease. J Natl Cancer Inst 1976;57:1037-43.
12. Ashley JB. Evidence for the existence of two forms of cervical carcinoma. J Obstet Gynaecol Br Commonw 1966;73:382-9.
13. Lawson JG. Cancer of the uterine cervix: some comments on earlier diagnosis. J Obstet Gynaecol Br Emp 1957;64:198-206.
14. Bain RW, Crocker DW. Rapid onset of cervical cancer in an upper socioeconomic group. Am J Obstet Gynecol 1983;146:366-71.
15. Hildesheim A, Hadjimichael O, Schwartz PE et al. Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol 1999;180:571-7.
16. Kinney W, Sawaya G, Sung HY. Stage at diagnosis and mortality in patients with adenocarcinoma and adenosquamous carcinoma of the uterine cervix diagnosed as a consequence of cytologic screening. Acta Cytol 2003;47:167-71.
17. Gustafsson L, Sparen P, Gustafsson M et al. Low efficiency of cytologic screening for cancer in situ of the cervix in older women. Int J Cancer 1995;63:804-9.
18. Kurman RJ, Schiffman M, Lancaster WD et al. Analysis of human papillomavirus types in cervical neoplasia: a possible role for type 18 in rapid progression. Am J Obstet Gynecol 1988;159:293-6.
19. Winer RL, Kiviat NB, Hughes JB et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191:731-8.
20. Sasieni P, Castanon A, Parkin DM. How many cervical cancers are prevented by treatment of screen-detected disease in young women? Int J Cancer 2009;124:461-4.
21. Vinkurova S, Wentzesen N, Kraus I et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 2008;68:307-18.
22. Wheeler CM, Hunt WC, Joste NE et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009;101:475-87.
23. Schwartz PE, Hadjimichael O, Lowell DM, Merino MJ, Janerich D. Rapidly progressive cervical cancer: the connectcut experience. Am J Obstet Gynecol 1996;175:1105-9.
24. Schiller W, Daro AF, Gollin HA, Primiano MD. Small preulcerative invasive carcinoma of the cervix: the spray carcinoma. Am J Obstet Gynecol 1953;65:1088-98.
25. Coleman DV, Poznansky JJ. Review of cervical smears from 76 women with invasive cervical cancer: cytological findings and medicolegal implications. Cytopathology 2006;17:127-36.
26. Baker RW, O'Sullivan JPO, Hanley J, Coleman DV. The characteristics of false negative cervical smears- implications for the UK cervical cancer screening programme. J Clin Pathol 1999;52:358-62.
27. Woodman CBJ, Collins S, Rollason TP et al. Human papillomavirus type 18 and rapidly progressing cervical carcinoma. Lancet 2003;361:40-3.
28. Sasieni P, Castanon A, Cuzick J. Effectiveness of screening with age: population based case-control study of prospectively recorded data. BMJ 2009;339:b2968.
29. Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003;89:88-93.
30. Antilla A, Ronco G. Working Group on the Registration and Monitoring of Cervical Cancer Screening Programmes in the European Union; within the European Network for Information on Cancer (EUNICE). Eur J Cancer 2009;45:2685-708.
31. Sasieni P, Castanon A, Parkin MD. Response to: why young women should be screened for cervical cancer: the distinction between CIN2 and CIN3. Int J Cancer 2010;126:2257-8.
32. Sigurdsson K. Cervical cancer: cytological screening in Iceland and implications of HPV vaccines. Cytopathology 2010;21:213-22.
33. Carozzi FM, Tornesello ML, Burroni E et al. Prevalence of human papillomavirus types in high grade cervical intraepithelial neoplasia and cancer in Italy. Cancer Epidemiol Biomarkers Prev 2010;19:2389-400.
34. Einstein MH, Martens MG, Garcia FA et al. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol Oncol 2010;118:116-22.
35. Castle P, Stoler MH, Wright TC et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25years and older: a subanalysis of the ATHENA Study. Lancet Oncol 2011;12:880-90.
36. American College of Obstetrics and Gynecology Committee on Practice Bulletins- Gynecology. Cervical cytology screening: ACOG practice bulletin No. 109. Obstet Gynecol 2009;114:1409-20.
37. Lancucki L, Fender M, Koukari A et al. A fall-off in cervical screening coverage of younger women in developed countries. J Med Screen 2010;17:91-6.
38. Jaramulowicz MR, Jenkins D, Barton SE et al. Cytological status and lesion size: a further dimension in cervical intraepithelial neoplasia. Br J Obstet Gynaecol 1989;96:1051-66.
39. Barton SE, Jenkins D, Hollingworth A, Cuzick J, Singer A. An explanation for the problem of false-negative smears. Br J Obstet Gynaecol 1989;96:482-5.
40. Rotman M, John M, Boyce J. Prognostic factors in cervical cancer. Cancer 1981;48:560-7.
41. Massad S, Einstein M, Myers E et al. The impact of human papillomavirus vaccination on cervical cancer prevention efforts. Gynecol Oncol 2009;114:360-4.
42. Brotherton JM, Fridman M, May CL et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011;377:2085-92.
43. Mitchell H, Hocking J, Saville M. Improvement in protection against adenocarcinoma of the cervix resulting from participation in cervical screening. Cancer Cytopathol 2003;99:336-41.
44. The International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8097 women with squamous cell carcinoma nd 1, 374 women with adenocarcinoma form 12 epidemiological studies. Int J Cancer 2006;120:885-91.
45. Sasieni P, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 2001;357:1490-3.
46. Boon ME, Alons-van Kordelaar JJM, Rietveld-Scheffers PEM. Consequences of the introduction of combined spatula and cytobrush sampling for cervical cytology: improvements in smear quality and detection rates. Acta Cytol 1986;30:264-70.
47. Kalir T, Simsir A, Demopoulos HB, Demopoulos RI. Obstacles to the early detection of endocervical adenocarcinoma. Int J Gynecol Pathol 2005;24:399-403.
48. Sherman ME, Dasgupta A, Schiffman M, Nayar R, Solomon D. The Bethesda Interobserver Reproducibility Study (BIRST): a web-based assessment of the Bethesda system for classifying cervical cytology. Cancer Cytopathol 2007;111:15-25.
49. Wright VC. Colposcopy of adenocarcinoma in situ and adenocarcinoma of the cervix. Differentiation from other lesions. J Low Genit Tract Dis 1999;3:84-7.
50. Kinney W, Fetterman B, Cox T et al. Characteristics of 44 cervical cancers diagnosed following Pap negative HPV positive screening in routine clinical practice. Gynecol Oncol 2011;121:309-13.
51. American Society for Colposcopy and Cervical Pathology, American Cancer Society, American Society for Clinical Pathology. Cervical Cancer Screening and Prevention: The Role of Molecular Testing Symposium. Working Group 2: Screening Strategies for Women 30Years and Older. Draft Recommendations. Available at: (accessed 5 November 2011).
52. Gonzalez PA, Hildesheim A, Rodriguez AC et al. Behavior/lifestyle and immunological factors associated with HPV infection among women older than 45years of age. Cancer Epidemiol Biomarkers Prev 2010;19:3044-54.
53. Roberts AD, Denholm RB, Cordiner JW. Cervical intraepithelial neoplasia in postmenopausal women with negative cervical cytology. Br Med J (Clin Res Ed) 1985;290:281.
54. Saminthen C, Lahoti C, Kanan V, Kline TS. Postmenopausal atypias: a diagnostic challenge. Diagn Cytopathol 1994;11:226-30.
55. Blesch KS, Prohaska TR. Cervical screening in older women. Cancer Nurs 1991;14:141-7.
56. Mandelblatt JS, Gopaul I, Wistrich M. Gynecologic care of elderly women: another look at Papanicolaou testing. JAMA 1986;256:367-71.
57. Zhao C, Zhao S, Heider A, Austin RM. Significance of high risk HPV DNA detection in women 50 and older with squamous cell Pap test abnormalities. Arch Pathol Lab Med 2010;134:1130-5.
58. Zhao C, Austin RM. Human papillomavirus DNA detection in ThinPrep Pap test vials is independent of cytologic sampling of the transformation zone. Gynecol Oncol 2007;107:231-5.
59. Gao FF, Austin RM, Zhao C. Histopathologic follow-up and human papillomavirus DNA test results in 290 patients with high grade squamous intraepithelial lesion Papanicolaou test results. Cancer Cytopathol 2011;119:377-86.
60. Bandyopadhyay S, Austin RM, Dabbs D, Zhao C. Adjunctive HPV DNA testing is a useful option in some clinical settings for disease risk assessment and triage of women with ASC-H Pap results. Arch Pathol Lab Med 2008;132:1874-81.
61. Sawaya GF, Sung HY, Kearney KA et al. Advancing age and cervical cancer screening and prognosis. J Am Geriatr Soc 2001;49:1499-504.
62. Wright JD, Gibb RK, Geevarghese S et al. Cervical carcinoma in the elderly: an analysis of patterns of care and outcome. Cancer 2005;103:85-91.
63. Schiffman M, Wacholder S. Success of HPV vaccination is now a matter of coverage. Lancet Oncol 2012;13:10-12.